Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans
Lyophilized (unreconstituted) BPC-157 can be stored frozen for long-term preservation, but once water is added, refrigeration at 2 to 8C is the correct storage method
Consult a healthcare provider familiar with peptide therapies for personalized guidance
ADP-ribosylation of RNA Beyond decorating RNA as a nucleotide analog, NAD + also provides the ADPR groups for the reversible mono-ADP-ribosylation of RNA phosphorylated ends
No peptide can outpace the damage caused by chronic hyperglycemia
